<DOC>
	<DOCNO>NCT00345826</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect dasatinib treat patient chronic myelogenous leukemia acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Dasatinib Treating Patients With Chronic Myelogenous Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine long-term safety tolerability dasatinib patient Philadelphia chromosome-positive chronic myelogenous leukemia acute lymphoblastic leukemia resistant intolerant imatinib mesylate . Secondary - Describe hematologic cytogenetic response patient treated drug . - Determine duration hematologic cytogenetic response patient use drug trial UCLA-0303035 . - Determine progression-free survival overall survival patient treated drug . OUTLINE : This open-label , roll-over study protocol UCLA-0303035 . Patients receive oral dasatinib twice daily 5 , 6 , 7 day . Treatment repeat every 7 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 54 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow hematologic malignancy : Chronic phase chronic myelogenous leukemia ( CML ) In complete hematologic response treatment protocol UCLA0303035 , indicate follow criterion : WBC ≤ upper limit normal ( ULN ) Platelet count &lt; 450,000/mm^3 No blast promyelocytes peripheral blood Less 5 % myelocyte plus metamyelocytes peripheral blood Peripheral blood basophil ≤ ULN No extramedullary involvement ( include hepatomegaly splenomegaly ) Response last ≥ 4 week first documentation Accelerated blastic phase CML acute lymphoblastic leukemia In major hematologic response* treatment protocol UCLA0303035 , define 1 following : In complete hematologic response* , indicate follow criterion : WBC ≤ ULN Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 No blast promyelocytes peripheral blood Bone marrow blast ≤ 5 % Less 5 % myelocyte plus metamyelocytes peripheral blood Peripheral blood basophil ≤ ULN No extramedullary involvement ( include hepatomegaly splenomegaly ) No evidence leukemia , indicate follow criterion : WBC ≤ ULN No blast promyelocytes peripheral blood Bone marrow blast ≤ 5 % Less 5 % myelocyte plus metamyelocytes peripheral blood Peripheral blood basophil ≤ ULN No extramedullary involvement ( include hepatomegaly splenomegaly ) Absolute neutrophil count ≥ 500/mm^3 &lt; 1,000/mm^3 AND platelet count ≥ 20,000/mm^3 &lt; 100,000/mm^3 In minor hematologic response* treatment protocol UCLA0303035 , indicate follow criterion : Less 15 % bone marrow &lt; 15 % peripheral blood Less 30 % blast plus promyelocytes bone marrow &lt; 30 % blast plus promyelocytes peripheral blood Less 20 % basophils peripheral blood No extramedullary disease spleen liver NOTE : *Response confirm ≥ 4 week allow provided concurrent anagrelide hydroxyurea time Philadelphia chromosomepositive ( Ph+ ) disease Resistant intolerant prior imatinib mesylate Received benefit ≥ 3 month prior therapy dasatinib protocol UCLA0303035 PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 week completion study treatment No serious uncontrolled medical disorder No active infection would preclude study participation No uncontrolled angina within past 3 month No diagnose suspect congenital long QT syndrome No history clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsades de pointes ) QTc ≤ 450 msec electrocardiogram No uncontrolled hypertension No dementia alter mental status would prohibit understanding rendering inform consent No history follow significant bleed disorder unrelated CML : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder past year ( e.g. , acquire antifactor VIII antibody ) Not involuntarily incarcerate either psychiatric physical ( e.g. , infectious disease ) illness No patient imprison No clinical adverse event , laboratory abnormality , intercurrent illness may preclude study treatment , opinion investigator Bilirubin &lt; 1.5 mg/dL ALT AST &lt; 2 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent use follow drug may confer risk torsades de pointes : Quinidine Procainamide Disopyramide Amiodarone Sotalol Ibutilide Dofetilide Erythromycin Clarithromycin Chlorpromazine Haloperidol Mesoridazine Thioridazine Pimozide Cisapride Bepridil Droperidol Methadone Arsenic Chloroquine Domperidone Halofantrine Levomethadyl Pentamidine Sparfloxacin Lidoflazine No concurrent treatment CML except hydroxyurea 2week duration No concurrent medication inhibit platelet function ( e.g. , aspirin , dipyridamole , epoprostenol , eptifibatide , clopidogrel , cilostazol , abciximab , ticlopidine , nonsteroidal antiinflammatory drug ) * except hydroxyurea anagrelide No concurrent anticoagulant ( e.g. , warfarin heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] ) except prophylaxis catheter thrombosis and/or heparin flush IV lines* NOTE : *Allowed receive previously UCLA0303035</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>